Cellectis S.A. Stock Analysis & AI Score
Cellectis S.A. (CLLS) has an ST Score of 29.5 (C-), driven by its Growth (B-) and held back by its Momentum (F). Analysts rate it Buy with a $2.15 price target (+50.3% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Cellectis S.A. (CLLS) has an ST Score of 29.5 (C-), driven by its Growth (B-) and held back by its Momentum (F). Analysts rate it Buy with a $2.15 price target (+50.3% upside).
- Strongest
- GrowthB-
- Weakest
- MomentumF
All factor grades
- GrowthB-
- ForecastC+
- ProfitabilityC
- SentimentC
- ValuationD+
- Financial StrengthD-
- MomentumF
- Piotroski2/9
Contact
CLLS stock: frequently asked questions
What is CLLS's ST Score?
Cellectis S.A. (CLLS) has an ST Score of 29.5 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is CLLS a buy, hold, or sell?
Analysts rate CLLS a Buy, with a price target of $2.15 (+50.3% vs the current price). Our ST Score grades it C- (29.5/100). The ST Score is a data-driven signal, not a recommendation.
What are CLLS's factor grades?
Valuation D+, Profitability C, Financial Strength D-, Momentum F, Growth B-, Forecast C+, Sentiment C.
What is CLLS's valuation grade?
Cellectis S.A. (CLLS) earns a valuation grade of D+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is CLLS's growth grade?
Cellectis S.A. (CLLS) earns a growth grade of B-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is CLLS's profitability grade?
Cellectis S.A. (CLLS) earns a profitability grade of C, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is CLLS's financial strength grade?
Cellectis S.A. (CLLS) earns a financial strength grade of D-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for CLLS?
The average analyst price target for Cellectis S.A. (CLLS) is $2.15 from 17 analysts, which is +50.3% versus the recent price of $1.43.
What is CLLS's Piotroski score?
Cellectis S.A. (CLLS) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.